Detalhe da pesquisa
1.
Evaluation of sex inequity in lung-cancer-specific survival.
Acta Oncol
; 63: 343-350, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38751329
2.
Distribution and characteristics of malignant tumours by lung lobe.
BMC Pulm Med
; 24(1): 106, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38439038
3.
Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015-2016.
BMC Cancer
; 22(1): 220, 2022 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35227226
4.
Factors affecting outcome in resected EGFR-mutated lung cancer.
Acta Oncol
; 61(6): 749-756, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35473448
5.
Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study.
Future Oncol
; 18(2): 205-214, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34784783
6.
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial.
Lancet Oncol
; 22(3): 321-331, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33662285
7.
Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors.
BMC Cancer
; 21(1): 1089, 2021 Oct 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34625038
8.
Epidemiology and outcome of peritoneal and pleural mesothelioma subtypes in Norway. A 20 year nation-wide study.
Acta Oncol
; 60(10): 1250-1256, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34313510
9.
Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy.
Acta Oncol
; 60(2): 149-156, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33356733
10.
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study.
Acta Oncol
; 60(12): 1565-1571, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34486915
11.
Cholangiocarcinoma treated with a tumour-agnostic drug. / Kolangiokarsinom behandlet med tumoragnostisk legemiddel.
Tidsskr Nor Laegeforen
; 1412021 09 07.
Artigo
em Norueguês
| MEDLINE | ID: mdl-34505477
12.
Lung cancer treated abroad with receptor tyrosine kinase inhibitor. / Lungekreft behandlet med reseptortyrosin=kinasehemmer i utlandet.
Tidsskr Nor Laegeforen
; 1412021 09 07.
Artigo
em Norueguês
| MEDLINE | ID: mdl-34505490
13.
Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy.
Int J Cancer
; 147(10): 2957-2966, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32468587
14.
The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases.
Scand J Immunol
; 92(2): e12893, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32433774
15.
Antibody combinations for optimized staining of macrophages in human lung tumours.
Scand J Immunol
; 92(1): e12889, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32299134
16.
Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016.
BMC Cancer
; 20(1): 488, 2020 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32473650
17.
Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC.
Acta Oncol
; 59(9): 1051-1057, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32543258
18.
A NOTCH added to metabolomics.
Br J Cancer
; 121(1): 3-4, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31114016
19.
Increase in curative treatment and survival of lung cancer in Norway 2001-2016.
Eur J Epidemiol
; 34(10): 951-955, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31313073
20.
Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease.
BMC Cancer
; 18(1): 739, 2018 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30005623